Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2012 7
2013 8
2014 5
2015 2
2016 4
2017 3
2018 7
2019 8
2020 12
2021 10
2022 6
2023 4
2024 3
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.
Ryan P, Blanco JL, Masia M, Garcia-Fraile L, Crusells MJ, Domingo P, Curran A, Guerri-Fernandez R, Bernal E, Bravo J, Revollo B, Macias J, Tiraboschi JM, Montejano R, Amador C, Torralba M, Merino D, Diaz-Brito V, Galindo MJ, Ferra S, Villoslada A, Losa JE, Fanjul FJ, Perez-Stachowski X, Peraire J, Portilla J, de la Fuente S, Dueñas C, Vazquez MJ, Di Gregorio S, Esteban H, Gil P, de Miguel M, Alejos B, Martínez E; PASO-DOBLE study group. Ryan P, et al. Among authors: alejos b. Lancet HIV. 2025 Jul;12(7):e473-e484. doi: 10.1016/S2352-3018(25)00105-5. Epub 2025 Jun 7. Lancet HIV. 2025. PMID: 40489982 Clinical Trial.
Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study.
Gutiérrez-Gutiérrez B, Del Toro MD, Borobia AM, Carcas A, Jarrín I, Yllescas M, Ryan P, Pachón J, Carratalà J, Berenguer J, Arribas JR, Rodríguez-Baño J; REIPI-SEIMC COVID-19 group and COVID@HULP groups. Gutiérrez-Gutiérrez B, et al. Lancet Infect Dis. 2021 Jun;21(6):783-792. doi: 10.1016/S1473-3099(21)00019-0. Epub 2021 Feb 23. Lancet Infect Dis. 2021. PMID: 33636145 Free PMC article.
Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks.
Suárez-García I, Alejos B, Moreno C, Martín Torres J, Masiá M, García-Fraile LJ, Riera M, Dalmau D, Rodríguez-Rosado R, Muga R, Moreno S, Jarrín I; CoRIS cohort. Suárez-García I, et al. Among authors: alejos b. J Antimicrob Chemother. 2025 Mar 3;80(3):682-691. doi: 10.1093/jac/dkae456. J Antimicrob Chemother. 2025. PMID: 39710424 Free PMC article.
Past and future of HIV infection. A document based on expert opinion.
Bouza E, Arribas JR, Alejos B, Bernardino JI, Coiras M, Coll P, Del Romero J, Fuster MJ, Górgolas M, Gutiérrez A, Gracia D, Hernando V, Martínez-Picado J, Martínez Sesmero JM, Martínez E, Moreno S, Mothe B, Navarro ML, Podzamczer D, Pulido F, Ramos JT, Ruiz-Mateos E, Suárez García I, Palomo E. Bouza E, et al. Among authors: alejos b. Rev Esp Quimioter. 2022 Apr;35(2):131-156. doi: 10.37201/req/083.2021. Epub 2022 Jan 12. Rev Esp Quimioter. 2022. PMID: 35018404 Free PMC article. Review.
Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717.
Perez-Molina JA, Pulido F, Di Giambenedetto S, Ribera E, Moreno S, Zamora J, Coscia C, Alejos B, Pitch J, Gatell JM, De Luca A, Arribas JR. Perez-Molina JA, et al. Among authors: alejos b. J Antimicrob Chemother. 2018 Nov 1;73(11):2927-2935. doi: 10.1093/jac/dky299. J Antimicrob Chemother. 2018. PMID: 30085184
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
Suárez-García I, Alejos B, Hernando V, Viñuela L, Vera García M, Rial-Crestelo D, Pérez Elías MJ, Albendín Iglesias H, Peraire J, Tiraboschi J, Díaz A, Moreno S, Jarrín I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Suárez-García I, et al. Among authors: alejos b. J Antimicrob Chemother. 2023 Jun 1;78(6):1423-1432. doi: 10.1093/jac/dkad102. J Antimicrob Chemother. 2023. PMID: 37099559 Free PMC article.
Unplanned pregnancies and social and partner support during pregnancy in Spanish women living with HIV.
Ruiz-Algueró M, Izquierdo R, Suárez-García I, Moreno C, Alejos B, Rava M, Moreno S, Montero Alonso M, Gutiérrez F, Gutierrez Cuellar I, Curran A, Hernando V, Jarrín I; Cohort of the Spanish HIV/AIDS Research Network (CoRIS). Ruiz-Algueró M, et al. Among authors: alejos b. HIV Med. 2023 Jun;24(6):727-737. doi: 10.1111/hiv.13469. Epub 2023 Feb 21. HIV Med. 2023. PMID: 36810955 Free article.
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study.
Díez C, Del Romero-Raposo J, Mican R, López JC, Blanco JR, Calzado S, Samperiz G, Portilla J, García-Fraile LJ, Gutiérrez F, Gómez-Sirvent JL, Suárez-García I, Amador C, Novella M, Arribas JR, Moreno S, González-García J, Jarrín I, Berenguer J; for CoRIS. Díez C, et al. HIV Med. 2021 Oct;22(9):867-876. doi: 10.1111/hiv.13145. Epub 2021 Jul 29. HIV Med. 2021. PMID: 34324783 Free PMC article.
77 results